The effect of soy isoflavones on non-alcoholic fatty liver disease and the level of fibroblast growth factor-21 and fetuin A
- PMID: 38429385
- PMCID: PMC10907727
- DOI: 10.1038/s41598-024-55747-6
The effect of soy isoflavones on non-alcoholic fatty liver disease and the level of fibroblast growth factor-21 and fetuin A
Abstract
A two-arm randomized open labeled controlled clinical trial was conducted on 50 patients with non-alcoholic fatty liver disease (NAFLD). Subjects were randomized to either receive two tablets of soy isoflavone (100 mg/day) or placebo. At week 12, the serum levels of alanine amino transferase (ALT), aspartate amino transferase (AST) and controlled attenuation parameter (CAP) score were significantly decreased only in the soy isoflavone group (P < 0.05). A significant decline in the gamma glutamyl transferase (GGT) level was observed only in the placebo group (P = 0.017). A significant increase in the serum level of fetuin A was shown in both groups at the end of the trial with a significantly greater increment in the soy isoflavone group compared to the placebo group (P < 0.05). The changes in the serum level of FGF-21 were not significant in any of the two groups. Steatosis grade significantly improved only in the soy isoflavone group (P = 0.045). There was no significant change in the fibrosis grade in the groups. Soy isoflavone intake led to a decrease in ALT, AST, CAP score, steatosis grade and an increase in the level of fetuin A. However, no significant changes were observed in the fibrosis grade and serum levels of GGT and FGF-21.
© 2024. The Author(s).
Conflict of interest statement
The authors declare no competing interests.
Similar articles
-
The effect of soy isoflavones supplementation on metabolic status in patients with non-alcoholic fatty liver disease: a randomized placebo controlled clinical trial.BMC Public Health. 2024 May 21;24(1):1362. doi: 10.1186/s12889-024-18812-3. BMC Public Health. 2024. PMID: 38773414 Free PMC article. Clinical Trial.
-
Vitamin E supplementation in the treatment on nonalcoholic fatty liver disease (NAFLD): Evidence from an umbrella review of meta-analysis on randomized controlled trials.J Dig Dis. 2023 Jun-Jul;24(6-7):380-389. doi: 10.1111/1751-2980.13210. Epub 2023 Sep 2. J Dig Dis. 2023. PMID: 37503812 Review.
-
Effectiveness of the pomegranate extract in improving hepatokines and serum biomarkers of non-alcoholic fatty liver disease: A randomized double blind clinical trial.Diabetes Metab Syndr. 2023 Jan;17(1):102693. doi: 10.1016/j.dsx.2022.102693. Epub 2022 Dec 13. Diabetes Metab Syndr. 2023. PMID: 36535123 Clinical Trial.
-
Efficacy of statins in treatment and development of non-alcoholic fatty liver disease and steatohepatitis: A systematic review and meta-analysis.Clin Res Hepatol Gastroenterol. 2022 Apr;46(4):101816. doi: 10.1016/j.clinre.2021.101816. Epub 2021 Oct 2. Clin Res Hepatol Gastroenterol. 2022. PMID: 34607067 Review.
-
Serum Fetuin-A Associated With Fatty Liver Index, Early Indicator of Nonalcoholic Fatty Liver Disease: A Strobe-Compliant Article.Medicine (Baltimore). 2015 Sep;94(39):e1517. doi: 10.1097/MD.0000000000001517. Medicine (Baltimore). 2015. PMID: 26426614 Free PMC article.
References
-
- Riazi K, Azhari H, Charette JH, Underwood FE, King JA, Afshar EE, et al. The prevalence and incidence of NAFLD worldwide: A systematic review and meta-analysis. Lancet Gastroenterol. Hepatol. 2022;20:25. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous